Emerging treatments for classical myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myeloproliferative neoplasms (MPN) management has advanced with JAK inhibitors like ruxolitinib.
• Ruxolitinib is approved for myelofibrosis and polycythemia vera (PV).
• Current treatments inadequately address major patient needs such as survival, cardiovascular risks, disease progression, and quality of life.

Purpose of the Study:

• To review the current landscape of novel therapies for MPN.
• To critically evaluate emerging treatments based on guidelines and risk stratification.
• To explore future directions toward a potential cure for MPN.

Main Methods:

• Review of current guidelines and patient risk stratification criteria.
• Analysis of previous clinical trial experiences with novel agents.
• Critical evaluation of preclinical rationale and early-phase clinical trial results.

Main Results:

• Ruxolitinib has shown benefits but has not fully addressed unmet needs in MPN.
• Some patients on interferon and ruxolitinib demonstrated reduced mutated allele burden.
• Early trials of novel MPN therapies have yielded disappointing results with dose-limiting toxicities.

Conclusions:

• Despite advances, significant unmet needs persist in MPN patient care.
• Novel targeted therapies are under investigation, often in combination with ruxolitinib.
• Further research is crucial to develop curative strategies for MPN.